ABNORMAL OCULAR MOVEMENTS IN PARKINSON'S DISEASE
Identifieur interne : 002625 ( Main/Corpus ); précédent : 002624; suivant : 002626ABNORMAL OCULAR MOVEMENTS IN PARKINSON'S DISEASE
Auteurs : O. Rascol ; M. Clanet ; J. L. Montastruc ; M. Simonetta ; M. J. Soulier-Esteve ; B. Doyon ; A. RascolSource :
- Brain [ 0006-8950 ] ; 1989-10.
Abstract
Quantitated automated electro-oculographic data from 45 parkinsonian patients were compared with those from 30 normal control subjects. Patients were selected with idiopathic Parkinson's disease without other associated neurological disease or dementia; 20 had never received antiparkinsonian drugs and in 25 such treatment had been stopped for at least 2 days. Saccade latency, amplitude and peak velocity, smooth pursuit peak velocity, optokinetic nystagmus (OKN) maximal and mean velocities and vestibulo-ocular reflex (VOR) suppression by vision or imagination were significantly altered in patients, whereas VOR gain in darkness was normal. Alterations of saccade latency and smooth pursuit peak velocity were more severe in the more advanced stages of the disease and saccade latency directed towards the symptomatic side was slightly delayed in hemiparkinsonian patients. Saccade amplitude improved 90 min after a single oral dose of L-DOPA. These results suggest a possible dopaminergic control of some ocular movements.
Url:
DOI: 10.1093/brain/112.5.1193
Links to Exploration step
ISTEX:C74C9012977CE0A28ADC589DD2DCC8234D915DBDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>ABNORMAL OCULAR MOVEMENTS IN PARKINSON'S DISEASE</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation><mods:affiliation>(Department of Medical and Clinical Pharmacology (INSERM U317) Toulouse, France)</mods:affiliation></affiliation><affiliation><mods:affiliation>(Department of Otoneurology Toulouse, France)</mods:affiliation></affiliation></author><author><name sortKey="Clanet, M" sort="Clanet, M" uniqKey="Clanet M" first="M." last="Clanet">M. Clanet</name><affiliation><mods:affiliation>(Department of Otoneurology Toulouse, France)</mods:affiliation></affiliation><affiliation><mods:affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</mods:affiliation></affiliation></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name><affiliation><mods:affiliation>(Department of Medical and Clinical Pharmacology (INSERM U317) Toulouse, France)</mods:affiliation></affiliation></author><author><name sortKey="Simonetta, M" sort="Simonetta, M" uniqKey="Simonetta M" first="M." last="Simonetta">M. Simonetta</name><affiliation><mods:affiliation>(Department of Otoneurology Toulouse, France)</mods:affiliation></affiliation><affiliation><mods:affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</mods:affiliation></affiliation></author><author><name sortKey="Soulier Esteve, M J" sort="Soulier Esteve, M J" uniqKey="Soulier Esteve M" first="M. J." last="Soulier-Esteve">M. J. Soulier-Esteve</name><affiliation><mods:affiliation>(Department of Otoneurology Toulouse, France)</mods:affiliation></affiliation></author><author><name sortKey="Doyon, B" sort="Doyon, B" uniqKey="Doyon B" first="B." last="Doyon">B. Doyon</name><affiliation><mods:affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</mods:affiliation></affiliation></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name><affiliation><mods:affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C74C9012977CE0A28ADC589DD2DCC8234D915DBD</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1093/brain/112.5.1193</idno><idno type="url">https://api.istex.fr/document/C74C9012977CE0A28ADC589DD2DCC8234D915DBD/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002625</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">ABNORMAL OCULAR MOVEMENTS IN PARKINSON'S DISEASE</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name><affiliation><mods:affiliation>(Department of Medical and Clinical Pharmacology (INSERM U317) Toulouse, France)</mods:affiliation></affiliation><affiliation><mods:affiliation>(Department of Otoneurology Toulouse, France)</mods:affiliation></affiliation></author><author><name sortKey="Clanet, M" sort="Clanet, M" uniqKey="Clanet M" first="M." last="Clanet">M. Clanet</name><affiliation><mods:affiliation>(Department of Otoneurology Toulouse, France)</mods:affiliation></affiliation><affiliation><mods:affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</mods:affiliation></affiliation></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name><affiliation><mods:affiliation>(Department of Medical and Clinical Pharmacology (INSERM U317) Toulouse, France)</mods:affiliation></affiliation></author><author><name sortKey="Simonetta, M" sort="Simonetta, M" uniqKey="Simonetta M" first="M." last="Simonetta">M. Simonetta</name><affiliation><mods:affiliation>(Department of Otoneurology Toulouse, France)</mods:affiliation></affiliation><affiliation><mods:affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</mods:affiliation></affiliation></author><author><name sortKey="Soulier Esteve, M J" sort="Soulier Esteve, M J" uniqKey="Soulier Esteve M" first="M. J." last="Soulier-Esteve">M. J. Soulier-Esteve</name><affiliation><mods:affiliation>(Department of Otoneurology Toulouse, France)</mods:affiliation></affiliation></author><author><name sortKey="Doyon, B" sort="Doyon, B" uniqKey="Doyon B" first="B." last="Doyon">B. Doyon</name><affiliation><mods:affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</mods:affiliation></affiliation></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name><affiliation><mods:affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Brain</title><idno type="ISSN">0006-8950</idno><idno type="eISSN">1460-2156</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="1989-10">1989-10</date><biblScope unit="volume">112</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="1193">1193</biblScope><biblScope unit="page" to="1214">1214</biblScope></imprint><idno type="ISSN">0006-8950</idno></series><idno type="istex">C74C9012977CE0A28ADC589DD2DCC8234D915DBD</idno><idno type="DOI">10.1093/brain/112.5.1193</idno><idno type="ArticleID">112.5.1193</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-8950</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Quantitated automated electro-oculographic data from 45 parkinsonian patients were compared with those from 30 normal control subjects. Patients were selected with idiopathic Parkinson's disease without other associated neurological disease or dementia; 20 had never received antiparkinsonian drugs and in 25 such treatment had been stopped for at least 2 days. Saccade latency, amplitude and peak velocity, smooth pursuit peak velocity, optokinetic nystagmus (OKN) maximal and mean velocities and vestibulo-ocular reflex (VOR) suppression by vision or imagination were significantly altered in patients, whereas VOR gain in darkness was normal. Alterations of saccade latency and smooth pursuit peak velocity were more severe in the more advanced stages of the disease and saccade latency directed towards the symptomatic side was slightly delayed in hemiparkinsonian patients. Saccade amplitude improved 90 min after a single oral dose of L-DOPA. These results suggest a possible dopaminergic control of some ocular movements.</div></front></TEI><istex><corpusName>oup</corpusName><author><json:item><name>O. RASCOL</name><affiliations><json:string>(Department of Medical and Clinical Pharmacology (INSERM U317) Toulouse, France)</json:string><json:string>(Department of Otoneurology Toulouse, France)</json:string><json:string>Correspondence to: Dr O Rascol, Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, 37 Allées Jules-Guesde, 31073 Toulouse Cedex, France</json:string></affiliations></json:item><json:item><name>M. CLANET</name><affiliations><json:string>(Department of Otoneurology Toulouse, France)</json:string><json:string>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</json:string></affiliations></json:item><json:item><name>J. L. MONTASTRUC</name><affiliations><json:string>(Department of Medical and Clinical Pharmacology (INSERM U317) Toulouse, France)</json:string></affiliations></json:item><json:item><name>M. SIMONETTA</name><affiliations><json:string>(Department of Otoneurology Toulouse, France)</json:string><json:string>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</json:string></affiliations></json:item><json:item><name>M. J. SOULIER-ESTEVE</name><affiliations><json:string>(Department of Otoneurology Toulouse, France)</json:string></affiliations></json:item><json:item><name>B. DOYON</name><affiliations><json:string>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</json:string></affiliations></json:item><json:item><name>A. RASCOL</name><affiliations><json:string>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Articles</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Quantitated automated electro-oculographic data from 45 parkinsonian patients were compared with those from 30 normal control subjects. Patients were selected with idiopathic Parkinson's disease without other associated neurological disease or dementia; 20 had never received antiparkinsonian drugs and in 25 such treatment had been stopped for at least 2 days. Saccade latency, amplitude and peak velocity, smooth pursuit peak velocity, optokinetic nystagmus (OKN) maximal and mean velocities and vestibulo-ocular reflex (VOR) suppression by vision or imagination were significantly altered in patients, whereas VOR gain in darkness was normal. Alterations of saccade latency and smooth pursuit peak velocity were more severe in the more advanced stages of the disease and saccade latency directed towards the symptomatic side was slightly delayed in hemiparkinsonian patients. Saccade amplitude improved 90 min after a single oral dose of L-DOPA. These results suggest a possible dopaminergic control of some ocular movements.</abstract><qualityIndicators><score>6.74</score><pdfVersion>1.3</pdfVersion><pdfPageSize>490 x 686 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>1</keywordCount><abstractCharCount>1028</abstractCharCount><pdfWordCount>9336</pdfWordCount><pdfCharCount>56393</pdfCharCount><pdfPageCount>22</pdfPageCount><abstractWordCount>145</abstractWordCount></qualityIndicators><title>ABNORMAL OCULAR MOVEMENTS IN PARKINSON'S DISEASE</title><genre><json:string>research-article</json:string></genre><host><volume>112</volume><pages><last>1214</last><first>1193</first></pages><issn><json:string>0006-8950</json:string></issn><issue>5</issue><genre></genre><language><json:string>unknown</json:string></language><eissn><json:string>1460-2156</json:string></eissn><title>Brain</title></host><categories><wos><json:string>CLINICAL NEUROLOGY</json:string><json:string>NEUROSCIENCES</json:string></wos></categories><publicationDate>1989</publicationDate><copyrightDate>1989</copyrightDate><doi><json:string>10.1093/brain/112.5.1193</json:string></doi><id>C74C9012977CE0A28ADC589DD2DCC8234D915DBD</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/C74C9012977CE0A28ADC589DD2DCC8234D915DBD/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/C74C9012977CE0A28ADC589DD2DCC8234D915DBD/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/C74C9012977CE0A28ADC589DD2DCC8234D915DBD/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">ABNORMAL OCULAR MOVEMENTS IN PARKINSON'S DISEASE</title><title level="a" type="sub">EVIDENCE FOR INVOLVEMENT OF DOPAMINERGIC SYSTEMS</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Oxford University Press</publisher><availability><p>OUP</p></availability><date>1989</date></publicationStmt><notesStmt><note>Correspondence to: Dr O Rascol, Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, 37 Allées Jules-Guesde, 31073 Toulouse Cedex, France</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">ABNORMAL OCULAR MOVEMENTS IN PARKINSON'S DISEASE</title><title level="a" type="sub">EVIDENCE FOR INVOLVEMENT OF DOPAMINERGIC SYSTEMS</title><author><persName><forename type="first">O.</forename><surname>RASCOL</surname></persName><affiliation>(Department of Medical and Clinical Pharmacology (INSERM U317) Toulouse, France)</affiliation><affiliation>(Department of Otoneurology Toulouse, France)</affiliation></author><author><persName><forename type="first">M.</forename><surname>CLANET</surname></persName><affiliation>(Department of Otoneurology Toulouse, France)</affiliation><affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</affiliation></author><author><persName><forename type="first">J. L.</forename><surname>MONTASTRUC</surname></persName><affiliation>(Department of Medical and Clinical Pharmacology (INSERM U317) Toulouse, France)</affiliation></author><author><persName><forename type="first">M.</forename><surname>SIMONETTA</surname></persName><affiliation>(Department of Otoneurology Toulouse, France)</affiliation><affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</affiliation></author><author><persName><forename type="first">M. J.</forename><surname>SOULIER-ESTEVE</surname></persName><affiliation>(Department of Otoneurology Toulouse, France)</affiliation></author><author><persName><forename type="first">B.</forename><surname>DOYON</surname></persName><affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</affiliation></author><author><persName><forename type="first">A.</forename><surname>RASCOL</surname></persName><affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</affiliation></author></analytic><monogr><title level="j">Brain</title><idno type="pISSN">0006-8950</idno><idno type="eISSN">1460-2156</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="1989-10"></date><biblScope unit="volume">112</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="1193">1193</biblScope><biblScope unit="page" to="1214">1214</biblScope></imprint></monogr><idno type="istex">C74C9012977CE0A28ADC589DD2DCC8234D915DBD</idno><idno type="DOI">10.1093/brain/112.5.1193</idno><idno type="ArticleID">112.5.1193</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1989</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Quantitated automated electro-oculographic data from 45 parkinsonian patients were compared with those from 30 normal control subjects. Patients were selected with idiopathic Parkinson's disease without other associated neurological disease or dementia; 20 had never received antiparkinsonian drugs and in 25 such treatment had been stopped for at least 2 days. Saccade latency, amplitude and peak velocity, smooth pursuit peak velocity, optokinetic nystagmus (OKN) maximal and mean velocities and vestibulo-ocular reflex (VOR) suppression by vision or imagination were significantly altered in patients, whereas VOR gain in darkness was normal. Alterations of saccade latency and smooth pursuit peak velocity were more severe in the more advanced stages of the disease and saccade latency directed towards the symptomatic side was slightly delayed in hemiparkinsonian patients. Saccade amplitude improved 90 min after a single oral dose of L-DOPA. These results suggest a possible dopaminergic control of some ocular movements.</p></abstract><textClass><keywords scheme="keyword"><list><item><term>Articles</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1989-10">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-14">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/C74C9012977CE0A28ADC589DD2DCC8234D915DBD/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus oup" wicri:toSee="no header"><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article"><front><journal-meta><journal-id journal-id-type="hwp">brain</journal-id><journal-id journal-id-type="publisher-id">brainj</journal-id><journal-id journal-id-type="pmc">brain</journal-id><journal-title>Brain</journal-title><issn pub-type="epub">1460-2156</issn><issn pub-type="ppub">0006-8950</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">112.5.1193</article-id><article-id pub-id-type="doi">10.1093/brain/112.5.1193</article-id><article-categories><subj-group><subject>Articles</subject></subj-group></article-categories><title-group><article-title>ABNORMAL OCULAR MOVEMENTS IN PARKINSON'S DISEASE</article-title><subtitle>EVIDENCE FOR INVOLVEMENT OF DOPAMINERGIC SYSTEMS</subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>RASCOL</surname><given-names>O.</given-names></name><xref ref-type="aff" rid="au1"><sup>1</sup></xref><xref ref-type="aff" rid="au2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>CLANET</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="au2"><sup>2</sup></xref><xref ref-type="aff" rid="au3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>MONTASTRUC</surname><given-names>J. L.</given-names></name><xref ref-type="aff" rid="au1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>SIMONETTA</surname><given-names>M.</given-names></name><xref ref-type="aff" rid="au2"><sup>2</sup></xref><xref ref-type="aff" rid="au3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>SOULIER-ESTEVE</surname><given-names>M. J.</given-names></name><xref ref-type="aff" rid="au2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>DOYON</surname><given-names>B.</given-names></name><xref ref-type="aff" rid="au3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>RASCOL</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="au3"><sup>3</sup></xref></contrib><aff id="au1"><sup>1</sup><institution>(Department of Medical and Clinical Pharmacology (INSERM U317)</institution> <addr-line>Toulouse, France)</addr-line></aff><aff id="au2"><sup>2</sup><institution>(Department of Otoneurology</institution> <addr-line>Toulouse, France)</addr-line></aff><aff id="au3"><sup>3</sup><institution>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan</institution> <addr-line>Toulouse, France)</addr-line></aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Dr O Rascol, Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, 37 Allées Jules-Guesde, 31073 Toulouse Cedex, France</corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>1989</year></pub-date><volume>112</volume><issue>5</issue><fpage>1193</fpage><lpage>1214</lpage><history><date date-type="received"><day>26</day><month>1</month><year>1988</year></date><date date-type="rev-recd"><day>22</day><month>11</month><year>1988</year></date><date date-type="accepted"><day>03</day><month>12</month><year>1988</year></date></history><copyright-statement>© Oxford University Press</copyright-statement><copyright-year>1989</copyright-year><abstract><p>Quantitated automated electro-oculographic data from 45 parkinsonian patients were compared with those from 30 normal control subjects. Patients were selected with idiopathic Parkinson's disease without other associated neurological disease or dementia; 20 had never received antiparkinsonian drugs and in 25 such treatment had been stopped for at least 2 days. Saccade latency, amplitude and peak velocity, smooth pursuit peak velocity, optokinetic nystagmus (OKN) maximal and mean velocities and vestibulo-ocular reflex (VOR) suppression by vision or imagination were significantly altered in patients, whereas VOR gain in darkness was normal. Alterations of saccade latency and smooth pursuit peak velocity were more severe in the more advanced stages of the disease and saccade latency directed towards the symptomatic side was slightly delayed in hemiparkinsonian patients. Saccade amplitude improved 90 min after a single oral dose of L-DOPA. These results suggest a possible dopaminergic control of some ocular movements.</p></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>ABNORMAL OCULAR MOVEMENTS IN PARKINSON'S DISEASE</title><subTitle>EVIDENCE FOR INVOLVEMENT OF DOPAMINERGIC SYSTEMS</subTitle></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>ABNORMAL OCULAR MOVEMENTS IN PARKINSON'S DISEASE</title><subTitle>EVIDENCE FOR INVOLVEMENT OF DOPAMINERGIC SYSTEMS</subTitle></titleInfo><name type="personal"><namePart type="given">O.</namePart><namePart type="family">RASCOL</namePart><affiliation>(Department of Medical and Clinical Pharmacology (INSERM U317) Toulouse, France)</affiliation><affiliation>(Department of Otoneurology Toulouse, France)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">CLANET</namePart><affiliation>(Department of Otoneurology Toulouse, France)</affiliation><affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. L.</namePart><namePart type="family">MONTASTRUC</namePart><affiliation>(Department of Medical and Clinical Pharmacology (INSERM U317) Toulouse, France)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">SIMONETTA</namePart><affiliation>(Department of Otoneurology Toulouse, France)</affiliation><affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. J.</namePart><namePart type="family">SOULIER-ESTEVE</namePart><affiliation>(Department of Otoneurology Toulouse, France)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">DOYON</namePart><affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">RASCOL</namePart><affiliation>(Neurology (INSERM U230), Centre Hospitalier Universitaire Purpan Toulouse, France)</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><subject><topic>Articles</topic></subject><originInfo><publisher>Oxford University Press</publisher><dateIssued encoding="w3cdtf">1989-10</dateIssued><copyrightDate encoding="w3cdtf">1989</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Quantitated automated electro-oculographic data from 45 parkinsonian patients were compared with those from 30 normal control subjects. Patients were selected with idiopathic Parkinson's disease without other associated neurological disease or dementia; 20 had never received antiparkinsonian drugs and in 25 such treatment had been stopped for at least 2 days. Saccade latency, amplitude and peak velocity, smooth pursuit peak velocity, optokinetic nystagmus (OKN) maximal and mean velocities and vestibulo-ocular reflex (VOR) suppression by vision or imagination were significantly altered in patients, whereas VOR gain in darkness was normal. Alterations of saccade latency and smooth pursuit peak velocity were more severe in the more advanced stages of the disease and saccade latency directed towards the symptomatic side was slightly delayed in hemiparkinsonian patients. Saccade amplitude improved 90 min after a single oral dose of L-DOPA. These results suggest a possible dopaminergic control of some ocular movements.</abstract><note type="author-notes">Correspondence to: Dr O Rascol, Laboratoire de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, 37 Allées Jules-Guesde, 31073 Toulouse Cedex, France</note><relatedItem type="host"><titleInfo><title>Brain</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0006-8950</identifier><identifier type="eISSN">1460-2156</identifier><identifier type="PublisherID">brainj</identifier><identifier type="PublisherID-hwp">brain</identifier><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>112</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>1193</start><end>1214</end></extent></part></relatedItem><identifier type="istex">C74C9012977CE0A28ADC589DD2DCC8234D915DBD</identifier><identifier type="DOI">10.1093/brain/112.5.1193</identifier><identifier type="ArticleID">112.5.1193</identifier><accessCondition type="use and reproduction" contentType="copyright">© Oxford University Press</accessCondition><recordInfo><recordContentSource>OUP</recordContentSource></recordInfo></mods></metadata><annexes><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/C74C9012977CE0A28ADC589DD2DCC8234D915DBD/annexes/pdf</uri></json:item></annexes><enrichments><istex:catWosTEI uri="https://api.istex.fr/document/C74C9012977CE0A28ADC589DD2DCC8234D915DBD/enrichments/catWos"><teiHeader><profileDesc><textClass><classCode scheme="WOS">CLINICAL NEUROLOGY</classCode><classCode scheme="WOS">NEUROSCIENCES</classCode></textClass></profileDesc></teiHeader></istex:catWosTEI></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002625 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002625 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:C74C9012977CE0A28ADC589DD2DCC8234D915DBD
|texte= ABNORMAL OCULAR MOVEMENTS IN PARKINSON'S DISEASE
}}
| This area was generated with Dilib version V0.6.23. |  |